GENOSYL
Commercial- Indications
- Neonatal hypoxic respiratory failure, Pulmonary hypertension
Company intelligence / Profile preview
VERO Biotech has developed and commercialized GENOSYL® Delivery System, the first FDA-approved tankless inhaled nitric oxide delivery system. The third-generation device is approved for use in hospitals and neonatal intensive care units, providing on-demand generation of inhaled nitric oxide without heavy gas tanks. Clinical adoption has been driven by its safety, portability, ease-of-use, and ability to address unmet needs in neonatal intensive care for PPHN. The company is expanding commercialization following recent funding.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on VERO Biotech.